Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) and the Oswald Cruz Foundation (Fiocruz) have entered into a collaboration to research and develop new medicines to treat diseases in the world's poorest countries, building on a long-standing relationship.
Subscribe to our email newsletter
GSK and Fiocruz have established a relationship in 1985 to manufacture vaccines for public health priorities in Brazil. These include polio, Haemophilus influenzae type b (Hib), measles, mumps, rubella, rotavirus and most recently pneumococcal disease.
The relationship has supported the development of research and manufacturing capabilities in Brazil through technology transfer and scientific collaboration.
The expanded partnership is expected to enable scientists at Fiocruz and GSK’s Tres Cantos facility in Spain to openly share new research, ideas and know-how.
The agreement will initially be focused on Chagas and Leishmaniasis because of the experience of Fiocruz in these areas and the severe burden of unmet medical need for patients living with these diseases.
GSK claimed that the new alliance is based on its open innovation strategy which intends to stimulate broad collaborative partnerships, providing access to the infrastructure, processes and experiences of scientists working in Tres Cantos and Fiocruz.
Tres Cantos Medicines Development Campus SVP and head Nick Cammack said that the expertise and knowledge that the scientists at Fiocruz would bring would help drive their discovery and development efforts.
Fiocruz Production and Innovation vice-president Carlos Gadelha said that with the agreement with the unit of Tres Cantos, Fiocruz would expand the partnership with GSK aiming to research and develop new drugs for neglected diseases.